Sumatriptan-d6 (succinate)

Sumatriptan-d6 (succinate)

• CAS Number: 1215621-31-0
• UNSPSC Description: Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research[1][2][3].
• Target Antigen: 5-HT Receptor; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling;Others
• Field of Research: Neurological Disease
• Purity: 99.63
• Solubility: H2O : 100 mg/mL (ultrasonic;warming)
• Smiles: OC(CCCC(CC(O)=O)C(O)=O.C(CN(C([2H])([2H])[2H])C([2H])([2H])[2H])C=1C=2C(NC1)=CC=C(CS(NC)(=O)=O)C2
• Molecular Weight: 419.53
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]S J Peroutka, et al. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol. 1989 Apr 12;163(1):133-6. |[3]K L Dechant, et al. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1992 May;43(5):776-98.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported